Drug search by name

Axicabtagene ciloleucel Intravenous and Inflammatory disorders

Result of checking the interaction of drug Axicabtagene ciloleucel Intravenous and disease Inflammatory disorders for safety when used together.

Check result:

Axicabtagene ciloleucel Intravenous <> Inflammatory disorders

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Drugs directed against B cells, such as axicabtagene ciloleucel, and tisagenlecleuce should not be administered to patients with inflammatory disorders. Cytokine Release Syndrome, including fatal or life-threatening reactions, occurred in patients receiving these agents. Axicabtagene ciloleucel and tisagenlecleuce are CD19-directed genetically modified autologous T cell immunotherapy that bind to CD19-expressing cancer cells and normal B cells and through a series of cascades, lead T cell activation and secretions of inflammatory cytokines.

Axicabtagene ciloleucel Intravenous

Generic Name: axicabtagene ciloleucel

Brand Name: Yescarta

Synonyms: Axicabtagene ciloleucel, Axicabtagene Ciloleucel

What is Axicabtagene ciloleucel Intravenous?